AM ResearchBioprinting

Aspect Biosystems Partners with Fraunhofer and InSCREENeX on 3DBioRing Bioprinted Muscle Tissue

Stay up to date with everything that is happening in the wonderful world of AM via our LinkedIn community.

Aspect Biosystems Ltd., a leader in the field of 3D bioprinting and tissue engineering, is collaborating with InSCREENeX GmbH (Braunschweig, Germany) and Fraunhofer ITEM (Institute for Toxicology and Experimental Medicine, Hannover, Germany) on the development of 3D printed contractile tissue within the 3DBioRing platform.

The research collaboration is supported by the National Research Council of Canada Industrial Research Assistance Program (NRC-IRAP) in Canada, and the Federal Ministry for Economic Affairs and Energy’s Central Innovation Program for SMEs (ZIM).

“We are excited to work with high profile international partners with unique technologies like InSCREENeX and Fraunhofer ITEM to expand the applications of our 3DBioRing muscle tissue platform and develop models of other tissues including blood vessels, heart, and lung. Ultimately, this collaboration will enable us to apply our Lab-on-a-Printer™ bioprinting technology to create novel tissues that can be used to improve the reliability of pre-clinical toxicity testing and could lead to the development of improved therapeutics for a host of vascular, cardiac, and respiratory diseases.” – Tamer Mohamed, President and CEO, Aspect Biosystems.

Aspect Biosystems Ltd. is a privately held biotechnology company operating at the leading edge of 3D bioprinting and tissue engineering. The company’s proprietary Lab-on-a-Printer™ platform technology is enabling advances in understanding fundamental biology, disease research, development of novel therapeutics, and regenerative medicine. In addition to its internal programs, Aspect is focused on strategically partnering with pharmaceutical and biotechnology companies, as well as academic researchers, to create physiologically and commercially relevant tissues. These tissues are used to advance and accelerate the discovery and development of new drugs and therapies.

“Personalized in vitro test systems that recreate the disease in a dish will take future drug development and regenerative medicine approaches to the next level. Aspect Biosystems’ bioprinting technology is at the forefront to develop three dimensional tissue with unmatched in-vivo like functionality. By partnering with Aspect Biosystems and Fraunhofer ITEM, and with the support from ZIM and IRAP, we will join forces to develop unique personalized cell systems. These expandable and physiologically relevant cell systems will be used as building blocks to bioprint contractile tissues with unparalleled physiology. This combined approach leads to an easy scalable and consistent production process for bioprinting in vitro tissues of highest quality in unlimited quantity.” – Dr. Tobias May, CEO, InSCREENeX

InSCREENeX GmbH is a privately held biotechnology company developing highly innovative cellular systems. The company’s proprietary and award-winning CI-SCREEN technology is an enabling tool creating in vitro cell systems with an in vivo like physiology and unlimited availability. These unique cell systems advance basic research and the drug development process. In addition, the universal applicability allows the creation of cell systems from any donor thereby supporting personalized medicine and disease-in-a-dish approaches. Through strategic partnering with biotechnology companies and academic researchers, these cell systems are used as building blocks for the creation of 3D tissues and organ-on-a-chip devices.

“Valid preclinical testing of new therapeutic drugs requires predictive and available test systems. Three-dimensional bioprinting enables the generation of human and physiological functional tissue in almost unlimited quantities and in standardized quality. These test systems will confirm that Aspect’s bioprinted tissues are optimised as reliable preclinical tools to identify the toxicity and efficacy of experimental therapeutics.” – Dr. Armin Braun, Division Director, Preclinical Pharmacology and in vitro Toxicology, Fraunhofer ITEM.

The Fraunhofer Institute for Toxicology and Experimental Medicine (ITEM) in Hannover conducts independent research projects, carries out funded public projects, and performs contract research. The Fraunhofer ITEM is one of the research institutes of the Fraunhofer-Gesellschaft, which conducts research at 69 institutes and research units throughout Germany, has a staff of 24,500, and files, on average, more than two patents every working day. Fraunhofer ITEM focuses on the development of translational disease models, diagnostic techniques, and innovative therapeutic approaches. Research activities range from toxicology and consumer protection to non-clinical and clinical drug research and development and safety testing. The division of preclinical pharmacology and in vitro toxicology has focused on the precision-cut tissue technology under the lead of Prof. Armin Braun for the past 10 years and has been pre-validated in three labs worldwide.


Research 2021
Ceramic AM Market Opportunities and Trends

This market study from 3dpbm Research provides an in-depth analysis and forecast of the ceramic additive ma...

3D Printing Media Network

3D Printing Media Network is the editorial branch of 3D Printing Business Directory. It was set up to provide the latest industry news and opinions to a global audience of professionals.
Back to top button

We use cookies to give you the best online experience. By agreeing you accept the use of cookies in accordance with our cookie policy.

Privacy Settings saved!
Privacy Settings

When you visit any web site, it may store or retrieve information on your browser, mostly in the form of cookies. Control your personal Cookie Services here.

These cookies are necessary for the website to function and cannot be switched off in our systems.

In order to use this website we use the following technically required cookies
  • wordpress_test_cookie
  • wordpress_logged_in_
  • wordpress_sec

Decline all Services
Accept all Services



Join industry leaders and receive the latest insights on what really matters in AM!

This information will never be shared with 3rd parties

I’ve read and accept the privacy policy.*